EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer

Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Beodeul Kang, Chan Kim, Hyo Sup Shim, Young Nyun Park, Sanghoon Jung, Sung Hoon Choi, Hye Jin Choi, Choong-Kun Lee, Hong Jae Chon

Cancer Research and Treatment · 15.10.2023 · 55 (4) · 1291-1302

DOI: 10.4143/crt.2022.1450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2023. Verfasst von Sung Hwan Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Kor…. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

There are clinical unmet needs in predicting therapeutic response and precise strategy for the patient with advanced biliary tract cancer (BTC). We aimed to identify genomic alterations predicting therapeutic response and resistance to gemcitabine and cisplatin (Gem/Cis)-based chemotherapy in advanced BTC.Materials and Methods Genomic analysis of advanced BTC multi-institutional cohorts was performed using targeted panel sequencing. Genomic alterations were analyzed integrating patients’ clinicopathologic data, including clinical outcomes of Gem/Cis-based therapy. Significance of genetic alterations was validated using clinical next-generation sequencing (NGS) cohorts from public repositories and drug sensitivity data from cancer cell lines.

Results

193 BTC patients from three cancer centers were analyzed. Most frequent genomic alterations were TP53 (55.5%), KRAS (22.8%), ARID1A (10.4%) alterations, and ERBB2 amplification (9.8%). Among 177 patients with BTC receiving Gem/Cis-based chemotherapy, ARID1A alteration was the only independent predictive molecular marker of primary resistance showing disease progression for 1st-line chemotherapy in the multivariate regression model (odds ratio, 3.12; p=0.046). In addition, ARID1A alteration was significantly correlated with inferior progression-free survival on Gem/Cis-based chemotherapy in the overall patient population (p=0.033) and in patients with extrahepatic cholangiocarcinoma (CCA) (p=0.041). External validation using public repository NGS revealed that ARID1A mutation was a significant predictor for poor survival in BTC patients. Investigation of multi-OMICs drug sensitivity data from cancer cell lines revealed that cisplatin-resistance was exclusively observed in ARID1A mutant bile duct cancer cells.

Conclusion

Integrative analysis with genomic alterations and clinical outcomes of the first-line Gem/Cis-based chemotherapy in advanced BTC revealed that patients with ARID1Aalterations showed a significant worse clinical outcome, especially in extrahepatic CCA. Well-designed prospective studies are mandatory to validate the predictive role of ARID1Amutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Duct NeoplasmsCholangiocarcinomaHumansGemcitabineCisplatinProspective StudiesDeoxycytidineMutationAntineoplastic Combined Chemotherapy ProtocolsBile Ducts, IntrahepaticHigh-Throughput Nucleotide SequencingDNA-Binding ProteinsTranscription Factors

Stichwörter der Autor:innen

ARID1ABiliary tract neoplasmsChemotherapyHigh-throughput nucleotide sequencing

Substanzen

GemcitabineCisplatinDeoxycytidineARID1A protein, humanDNA-Binding ProteinsTranscription Factors

Autor:innen und Institutionen

  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Radiology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Lee, S. H., Cheon, J., Lee, S., Kang, B., Kim, C., Shim, H. S., Park, Y. N., Jung, S., Choi, S. H., Choi, H. J., Lee, C. K., & Chon, H. J. (2023). ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer. Cancer Research and Treatment, 55(4), 1291-1302. https://doi.org/10.4143/crt.2022.1450

Vancouver

Lee SH, Cheon J, Lee S, Kang B, Kim C, Shim HS, et al. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer. Cancer Research and Treatment. 2023;55(4):1291-1302. doi:10.4143/crt.2022.1450

BibTeX
@article{Lee2023,
  author = {Lee, Sung Hwan and Cheon, Jaekyung and Lee, Seoyoung and Kang, Beodeul and Kim, Chan and Shim, Hyo Sup and Park, Young Nyun and Jung, Sanghoon and Choi, Sung Hoon and Choi, Hye Jin and Lee, Choong-Kun and Chon, Hong Jae},
  title = {ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer},
  journal = {Cancer Research and Treatment},
  year = {2023},
  volume = {55},
  number = {4},
  pages = {1291--1302},
  doi = {10.4143/crt.2022.1450}
}
Kostenlos starten →